Stay updated on IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page.

Latest updates to the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page
- Check2 days agoChange DetectedAdded Results Posted and expanded study details, including Non-Randomized design, Phase 1 and Phase 2 arms, and dosing regimens for Indoximod with Gemcitabine and Nab-Paclitaxel, along with updates to outcomes such as Overall Survival and Progression-Free Survival.SummaryDifference3%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page now displays Revision: v3.5.0 instead of Revision: v3.4.3.SummaryDifference0.0%

- Check31 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.0%

- Check59 days agoChange DetectedMinor UI/version change: the page footer now shows Revision: v3.4.2, replacing v3.4.1; this does not affect core content, data, or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1; a minor UI update that does not affect study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check73 days agoChange DetectedGlossary is now shown to help users understand trial terms. Minor metadata updates include capitalization adjustments for QC-related labels and a new Revision: v3.4.0 entry.SummaryDifference0.2%

Stay in the know with updates to IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page.